31 March 2017
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Posting of Annual Report & Notice of AGM
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, confirms that the Annual Report and Accounts for the year ended 31 December 2016 ("2016 Annual Report and Accounts"), the Notice of the Annual General Meeting ("AGM") and a Form of Proxy have been posted to shareholders.
The AGM is to be held at 11am on 26 April at London Heathrow Marriott Hotel, Bath Rd, Harlington, Hayes UB3 5AN.
A copy of the 2016 Annual Report and Accounts and other documents are available on the Company's website: http://vennlifesciences.com/
Enquiries:
Venn Life Sciences Holdings Plc |
|
|
Allan Wood, Non-Executive Chairman |
|
|
Tony Richardson, Chief Executive Officer |
Tel: +353 1 5499341 |
|
|
|
|
Davy (Nominated Adviser and Broker) |
|
|
Fergal Meegan / Matthew de Vere White (Corporate Finance) |
Tel: +353 1 679 6363 |
|
Orla Bolger (Corporate Broking) |
|
|
|
|
|
Hybridan LLP (Co-Broker) |
Tel: +44 (0)20 3764 2341 |
|
Claire Louise Noyce |
|
|
|
|
|
Walbrook PR Ltd |
Tel: +44(0)20 7933 8787 |
|
|
|
|
|
|
|